Expertise in
5
conditions

Dr. Jason B. Kaplan

Hematology
Office
2650 Ridge Ave, 
Evanston, IL 
Expertise in
5
conditions
Office
2650 Ridge Ave, 
Evanston, IL 

Overview

Jason Kaplan is a Hematologist practicing medicine in Evanston, Illinois.

Dr. Kaplan is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, B-Cell Lymphoma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 49 peer reviewed articles and participating in 10 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in IL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Office
2650 Ridge Ave, Evanston, IL 60201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
Enrollment Status: Completed
Publish Date: June 10, 2026
Intervention Type: Drug, Other
Study Drug: Ibrutinib
Study Phase: Phase 2
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Enrollment Status: Completed
Publish Date: June 12, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Nivolumab, Veliparib
Study Phase: Phase 1
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
Enrollment Status: Unknown
Publish Date: June 02, 2023
Intervention Type: Procedure, Drug, Radiation, Other, Biological
Study Drugs: Dacarbazine, Doxorubicin, Pembrolizumab, Vinblastine, 18F-Fludeoxyglucose
Study Phase: Phase 2
Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Unknown
Publish Date: June 02, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Pembrolizumab
Study Phase: Phase 2
Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: January 25, 2022
Intervention Type: Radiation, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 1
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Drug
Study Drugs: INCB053914, I-DAC (Intermediate Dose Cytarabine), Azacitidine, Ruxolitinib
Study Phase: Phase 1/Phase 2
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
Enrollment Status: Terminated
Publish Date: July 16, 2020
Intervention Type: Biological, Other
Study Phase: Phase 2
A Phase 1, Single Arm, Single Center Pilot Study of Medi4736, an Anti-Pdl1 Therapy, for Patients With Myelofibrosis
A Phase 1, Single Arm, Single Center Pilot Study of Medi4736, an Anti-Pdl1 Therapy, for Patients With Myelofibrosis
Enrollment Status: Withdrawn
Publish Date: August 20, 2019
Intervention Type: Biological, Other
Study Phase: Phase 1
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Enrollment Status: Terminated
Publish Date: May 01, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

49 Total Publications

Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.
Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 24, 2025
Similar Doctors
Expertise in
26
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Expertise in
26
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Referral may be required

UChicago Medicine River East

355 E. Grand Ave., 
Chicago, IL 
 (12.5 miles away)
888-824-0200
Languages Spoken:
English, Greek, Gujarati , Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonali Smith is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Smith is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is board certified in Medical Oncology and Practicing Since2001. Dr. Smith is currently accepting new patients.

Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
Referral may be required
Before you request
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (12.3 miles away)
866-587-4322
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leo Gordon is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Gordon is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Gordon is board certified in American Board Of Internal Medicine - Hematology (Certified). Dr. Gordon is currently accepting new patients.

Expertise in
25
conditions
Dr. Reem M. Karmali
Hematology | Oncology
Expertise in
25
conditions
Dr. Reem M. Karmali
Hematology | Oncology
Referral may be required
Before you request
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (12.3 miles away)
866-587-4322
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Reem Karmali is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Karmali is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Karmali is board certified in American Board Of Internal Medicine - Hematology (Certified). Dr. Karmali is currently accepting new patients.

Frequently Asked Questions about Dr. Jason B. Kaplan

How do I make an appointment with Dr. Jason B. Kaplan?

You can book an appointment with Dr. Jason B. Kaplan by calling their office at 847-570-2183. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jason B. Kaplan a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jason B. Kaplan is classified as an Advanced expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jason B. Kaplan specialize in?

While Dr. Jason B. Kaplan is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jason B. Kaplan participate in research or clinical trials?

Yes. Dr. Jason B. Kaplan has published 49 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Jason B. Kaplan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jason B. Kaplan accept my insurance?

Dr. Jason B. Kaplan accepts most major insurance plans, including Aetna and Humana. We recommend calling the office directly at 847-570-2183 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kaplan's expertise for a condition
ConditionClose
      View All 56 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile